Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dialysis in 2011

Can cardiovascular risk in dialysis patients be decreased?

More than 1.4 million patients are on renal replacement therapy worldwide. Mortality in patients with end-stage renal disease (ESRD) is as high as that seen in some types of metastatic cancer, and premature cardiovascular disease is the major killer in ESRD. Several publications in 2011 addressed how interventions can modify cardiovascular risk factors and improve outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Carrero, J. J. & Stenvinkel, P. Of persistent inflammation as a catalyst for other risk factors in chronic kidney disease. a hypothesis proposal. Clin. J. Am. Soc. Nephrol. 4, S49–S55 (2009).

    Article  CAS  Google Scholar 

  2. Tripepi, G. et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol. 7, 1714–1721 (2011).

    Article  Google Scholar 

  3. Hung, A. M., Ellis, C. D., Shintani, A., Booker, C. & Ikizler, T. A. IL-1β receptor antagonist reduces inflammation in hemodialysis patients. J. Am. Soc. Nephrol. 22, 437–442 (2011).

    Article  CAS  Google Scholar 

  4. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).

    Article  CAS  Google Scholar 

  5. Holdaas, H. et al. Rosuvastatin in diabetic hemodialysis patients. J. Am. Soc. Nephrol. 22, 1335–1341 (2011).

    Article  CAS  Google Scholar 

  6. Winkelmayer, W. C., Patrick, A. R., Liu, J., Brookhart, M. A. & Setoguchi, S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 22, 349–357 (2011).

    Article  Google Scholar 

  7. Winkelmayer, W. C., Liu, J., Setoguchi, S. & Choudhry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.04550511.

  8. Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).

    Article  CAS  Google Scholar 

  9. Eknoyan, G. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 347, 2010–2019 (2002).

    Article  Google Scholar 

  10. Chertow, G. M. et al. In-center hemodialysis six times per week versus three times per week. N. Engl. J. Med. 363, 2287–2300 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter Stenvinkel.

Ethics declarations

Competing interests

P. Stenvinkel declares an association with the following company: Gambro (scientific advisor). P. Bárány declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stenvinkel, P., Bárány, P. Can cardiovascular risk in dialysis patients be decreased?. Nat Rev Nephrol 8, 72–74 (2012). https://doi.org/10.1038/nrneph.2011.212

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2011.212

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing